Survival disparities between Ma¯ori and non-Ma¯ori men with prostate cancer in New Zealand

BJU International

Volumn 115, Issue S5, 2015, Pages 24-30

  Obertová, Zuzana ^a   Scott, Nina ^b   Brown, Charis ^a   Stewart, Alistair ^c   Lawrenson, Ross ^a  

^a UNIVERSITY OF AUCKLAND   (New Zealand)

^b UNIVERSITY OF AUCKLAND   (New Zealand)

^c WAIKATO DISTRICT HEALTH BOARD   (New Zealand)

Author keywords

indigenous; outcomes; prostate cancer; survival; temporal changes

Indexed keywords

ADULT; AGED; ARTICLE; CANCER MORTALITY; CANCER SPECIFIC SURVIVAL; CAUCASIAN; COHORT ANALYSIS; CONTROLLED STUDY; DIAGNOSIS; EPIDEMIOLOGY; ETHNIC DIFFERENCE; ETHNOLOGY; HEALTH DISPARITY; HUMAN; KAPLAN MEIER METHOD; MAJOR CLINICAL STUDY; MALE; MAORI (PEOPLE); MORTALITY; NEW ZEALAND; OCEANIC ANCESTRY GROUP; PRIORITY JOURNAL; PROSTATE CANCER; PROSTATIC NEOPLASMS; STATISTICS AND NUMERICAL DATA; SURVIVAL RATE; TREATMENT OUTCOME;

AGED; COHORT STUDIES; DIAGNOSIS; EPIDEMIOLOGY; ETHNOLOGY; EUROPEAN CONTINENTAL ANCESTRY GROUP; HUMANS; KAPLAN-MEIER ESTIMATE; MALE; MORTALITY; NEW ZEALAND; OCEANIC ANCESTRY GROUP; PROSTATIC NEOPLASMS; STATISTICS AND NUMERICAL DATA; TREATMENT OUTCOME;

EID: 84964240675     PISSN: 14644096     EISSN: 1464410X     Source Type: Journal    
DOI: 10.1111/bju.12900     Document Type: Article

References (45)

1. Ferlay J, Shin HR, Bray F, Forman D, Mathers C, Parkin DM,. GLOBOCAN 2008 v1.2. IARC CancerBase No. 10, Lyon: International Agency for Research on Cancer, 2010. Available at: http://globocan.iarc.fr. Accessed July 2011
2. Baade PD, Youlden DR, Krnjacki LJ,. International epidemiology of prostate cancer: geographical distribution and secular trends. Mol Nutr Food Res 2009; 53: 171-184
3. Siegel R, Naishadham D, Jemal A,. Cancer statistics, 2013. CA Cancer J Clin 2013; 63: 11-30
4. Obertová Z, Lawrenson R, Hodgson F, et al. Screening for prostate cancer in New Zealand general practice. J Med Screen 2013; 20: 49-51
5. Williams N, Hughes LJ, Turner EL, et al. Prostate-specific antigen testing rates remain low in UK general practice: a cross-sectional study in six English cities. BJU Int 2011; 108: 1402-1408
6. Bramley D, Herbert P, Jackson R, Chassin M,. Indigenous disparities in disease-specific mortality, a cross-country comparison: New Zealand, Australia, Canada and the United States. N Z Med J 2004; 117: U1215
7. Jeffreys M, Stevanovic V, Tobias M, et al. Ethnic inequalities in cancer survival in New Zealand: linkage study. Am J Public Health 2005; 95: 834-837
8. Jemal A, Siegel R, Xu J, Ward E,. Cancer statistics, 2010. CA Cancer J Clin 2010; 60: 277-300
9. Valery PC, Coory M, Stirling J, Green AC,. Cancer diagnosis, treatment, and survival in Indigenous and non-Indigenous Australians: a matched cohort study. Lancet 2006; 367: 1842-1848
10. Clegg LX, Li FP, Hankey BF, Chu K, Edwards BK,. Cancer survival among US Whites and minorities. Arch Intern Med 2002; 162: 1985-1993
11. Moore SP, O'Rourke PK, Mallitt KA, et al. Cancer incidence and mortality in Indigenous Australians in Queensland, 1997-2006. Med J Aust 2010; 193: 590-593
12. Morrell S, You H, Baler D,. Estimates of cancer incidence, mortality and survival in aboriginal people from NSW, Australia. BMC Cancer 2012; 12: 168. Available at: http://www.biomedcentral.com/1471-2407/12/168. Accessed August 2014
13. Statistics New Zealand. New Zealand in Profile 2011. Wellington: Statistics New Zealand, 2011. Available at: http://www.stats.govt.nz/browse-for-stats/snapshots-of-nz/nz-in-profile-2011.aspx. Accessed August 2014
14. Ministry of Health. Cancer: New Registrations and Deaths 2010. Wellington: Ministry of Health, 2013. Available at: http://www.health.govt.nz/publication/cancer-new-registrations-and-deaths-2010. Accessed August 2014
15. Haynes R, Pearce J, Barnett R,. Cancer survival in New Zealand: ethnic, social and geographical inequalities. Soc Sci Med 2008; 67: 928-937
16. Sneyd MJ,. Ethnic differences in prostate cancer survival in New Zealand: a national study. Cancer Causes Control 2008; 19: 993-999
17. Jeffreys M, Sarfati D, Stevanovic V, et al. Socioeconomic inequalities in cancer survival in New Zealand: the role of extent at disease at diagnosis. Cancer Epidemiol Biomarkers Prev 2009; 18: 915-921
18. Hill S, Sarfati D, Blakely T, et al. Survival disparities in Indigenous and non-Indigenous New Zealanders with colon cancer: the role of patient comorbidity, treatment and health service factors. J Epidemiol Community Health 2010; 64: 117-123
19. Hill S, Sarfati D, Robson B, Blakely T,. Indigenous inequities in cancer: what role for health care? ANZ J Surg 2013; 83: 36-41
20. McLeod M, Harris R, Purdie G, Cormack D, Robson B,. Improving survival disparities in cervical cancer between Maori and non-Maori women in New Zealand: a national retrospective cohort study. Aust N Z J Public Health 2010; 34: 193-199
21. Sarfati D, Blakely T, Shaw C, Cormack D, Atkinson J,. Patterns of disparity: ethnic and socio-economic trends in breast cancer mortality in New Zealand. Cancer Causes Control 2006; 17: 671-678
22. Stevens W, Stevens G, Kolbe J, Cox B,. Ethnic differences in the management of lung cancer in New Zealand. J Thorac Oncol 2008; 3: 237-244
23. Salmond C, King P, Crampton P, Waldegrave C,. NZiDep: a New Zealand index of socioeconomic deprivation for individuals. Soc Sci Med 2006; 62: 1474-1485
24. Statistics New Zealand. New Zealand: An Urban/Rural Profile. Wellington: Statistics New Zealand, 2005: Available at: http://www.stats.govt.nz/browse-for-stats/people-and-communities/Geographic-areas/urban-rural-profile.aspx. Accessed February 2014
25. Du XL, Lin CC, Johnson NJ, Altekruse S,. Effects of individual-level socioeconomic factors on racial disparities in cancer treatment and survival. Cancer 2011; 117: 3242-3251
26. Freedland SJ, Isaacs WB,. Explaining racial differences in prostate cancer in the United States: sociology or biology? Prostate 2005; 62: 243-252
27. Hall SE, Holman CD, Wisniewski ZS, Semmens J,. Prostate cancer: socio-economic, geographical and private-health insurance effects on care and survival. BJU Int 2005; 95: 51-58
28. Tewari A, Horninger W, Pelzer AE, et al. Factors contributing to the racial differences in prostate cancer mortality. BJU Int 2005; 96: 1247-1252
29. Statistics New Zealand. New Zealand Life Tables: 2005-07. Wellington: Statistics New Zealand, 2009. Available at: http://www.stats.govt.nz/browse-for-stats/health/life-expectancy/new-zealand-life-tables-2005-07.aspx. Accessed August 2014
30. Hill S, Sarfati D, Blakely T, et al. Ethnicity and management of colon cancer in New Zealand: do indigenous patients get a worse deal? Cancer 2010; 116: 3205-3214
31. Albertsen PC, Hanley JA, Fine J,. 20-year outcomes following conservative management of clinically localised prostate cancer. JAMA 2005; 293: 2095-2101
32. Johansson JE, Holmberg L, Johansson S, Bergström R, Adami HO,. Fifteen-year survival in prostate cancer. A prospective, population-based study in Sweden. JAMA 1997; 277: 467-471
33. Halabi S, Small EJ, Kantoff PW, et al. Prognostic model for predicting survival in men with hormone-refractory metastatic prostate cancer. J Clin Oncol 2003; 21: 1232-1237
34. Merrill RM, Lyon JL,. Explaining the difference in prostate cancer mortality rates between white and black men in the United States. Urology 2000; 55: 730-735
35. Oakley-Girvan I, Kolonel LN, Gallagher RP, Wu AH, Felberg A, Whittemore AS,. Stage at diagnosis and survival in a multiethnic cohort of prostate cancer patients. Am J Public Health 2003; 93: 1753-1759
36. Obertová Z, Lawrenson R, Scott N, et al. Treatment modalities for Ma¯ori and NZ European men with localised prostate cancer. Int J Clin Oncol 2015; doi: 10.1007/s10147-014-0781-4
37. Cohn JA, Dangle PP, Wang CE, et al. The prognostic significance of perineural invasion and race in men considering active surveillance. BJU Int 2014; 114: 75-80
38. Chong CCW, Austen L, Kneebone A, Lalak A, Jalaludin B,. Patterns of practice in the management of prostate cancer: results from multidisciplinary surveys of clinicians in Australia and New Zealand in 1995 and 2000. BJU Int 2006; 97: 975-980
39. Smart R,. Outcomes of transrectal ultrasound scan of the prostate with sector biopsies for 323 New Zealand men with suspicion of prostate cancer. N Z Med J 1999; 112: 465-469
40. Wilcox CB, Gilbourd D, Louie-Johnsun M,. Anxiety and health-related quality of life (HRQL) in patients undergoing active surveillance of prostate cancer in an Australian centre. BJU Int 2014; 113 (Suppl.): 64-68
41. Bechis SK, Carroll PR, Cooperberg MR,. Impact of age at diagnosis on prostate cancer treatment and survival. J Clin Oncol 2011; 29: 235-241
42. Hamilton AS, Albertsen PC, Johnson TK, et al. Trends in the treatment of localized prostate cancer using supplemented cancer registry data. BJU Int 2010; 107: 576-584
43. Harlan LC, Potosky A, Gilliland FD, et al. Factors associated with initial therapy for clinically localized prostate cancer: prostate cancer outcomes study. J Natl Cancer Inst 2001; 93: 1864-1871
44. Husson O, van Steenbergen LN, Koldewijn EL, et al. Patients with prostate cancer continue to have excess mortality up to 15 years after diagnosis. BJU Int 2014; 114: 691-697
45. Evans SM, Millar JL, Davis ID, et al. Patterns of care for men diagnosed with prostate cancer in Victoria from 2008 to 2011. Med J Aust 2013; 198: 540-545